Plasma Fractionation Market – Global Regional Analysis, Growth Drivers and Forecast to 2024

Press Release

Plasma fractionation is a method used for segregating plasma into its different components. Proteins present in plasma are mainly used for therapeutic purposes in the treatment of various diseases. Factors primarily responsible for the growth of the global plasma fractionation market are increased prevalence of rare diseases, surge in geriatric population, and growing use of immunoglobulins in different therapeutic domains.

On the basis of product type, the plasma fractionation market is categorized into immunoglobulins, coagulation factors, albumins, and protein inhibitors, wherein immunoglobulins hold the largest revenue share in the market. This is attributed to the rising prevalence of primary immunodeficiency disease (PIDD). For instance, treatment of PIDD is mainly dependent upon regular infusion therapy where immunoglobulins are involved in the treatment procedure. The market for albumins is expected to observe the fastest growth, owing to rapid use of the products in various drug formulations, especially for drugs used in treatment of acute liver diseases.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample

The major growth driver for the plasma fractionation industry is the rising number of patients suffering from rare autoimmune diseases. According to the facts stated by National Institute of Environmental Health Sciences (NIEHS) in 2018, rare autoimmune diseases affect more than 23.5 million people in the U.S. Moreover, NIEHS also supports various clinical research institutes on how immunity and environmental factors work together to compromise the body’s ability to defend itself, and develop into autoimmune diseases. For instance, National Toxicology Program (NTP) by NIEHS is involved in researching on the link between genetic predisposition and environmental triggers.

Rising prevalence rate of immunodeficiency diseases also serves as a key driving factor for the plasma fractionation market growth. PIDD, multiple sclerosis, and immune thrombocytopenia purpura (ITP) are some of the examples of rare immune diseases that have high prevalence rate, globally. According to the reports by Immune Deficiency Foundation (IDF), in 2018, there were approximately 250,000 people diagnosed with PIDD.

Key Players Operating in the Plasma Fractionation Market:

1- CSL Behring

2- Japan Blood Products Organization

3- Green Cross Corp.

4- Bio Product Laboratory Ltd.

5- Octapharma AG

6- Kedrion S.p.A.

7- Grifols International S.A.

This post was originally published on Financial Sector

Comments are closed.